In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Longer feasibility potential of bioresorbable stents

ESC Congress News 2015 - London

A drug-eluting stent made from bioresorbable material showed similar mid-term (12 month) safety and efficacy to a metal stent in patients undergoing PCI in the ABSORB Japan study and lays ‘a solid foundation’ for continued evaluation of long term outcomes for bioresorbable stents.

Invasive and Interventional Cardiology, Cardiovascular Surgery


Takeshi Kimura:ABSORB Japan results support feasibility of bioresorbable stents for long-term use.A drug-eluting stent made from bioresorbable material showed similar mid-term (12 month) safety and efficacy to a metal stent in patients undergoing PCI in the ABSORB Japan study and lays ‘a solid foundation’ for continued evaluation of long term outcomes for bioresorbable stents.

Study presenter Takeshi Kimura from Kyoto University Hospital said: ‘These results support the feasibility of bioresorbable vascular scaffolds to potentially improve longterm outcomes of patients.’

Theoretically, bioresorbable vascular scaffolds (BVS) may provide superior long-term results compared with permanent metallic DES, but whether they are as safe and effective as the metallic DES prior to complete bioresorption has been unknown.

In this ABSORB study, performed between April and December 2013, 400 patients with up to two de novo target lesions were randomised 2:1 to PCI using either BVS (n = 266) or metallic DES (n = 134). The study took place at 38 investigational sites in Japan.

The primary endpoint of target lesion failure (a composite of cardiac death, MI attributable to target vessel, or ischemiadriven target lesion revascularisation at one year) occurred in 4.2% of the BVS patients and 3.8% of the metallic DES patients (RR 1.10; 95% CI 0.39-3.11), demonstrating noninferiority for the bioresorbable stent (P<0.0001). Definite or probable stent scaffold thrombosis at 12 months occurred in 1.5% of patients with both devices. Procedure duration , however, was significantly longer for the bioresorbable stent.

‘These results support the feasibility of BVS use to potentially improve the long-term outcomes of patients undergoing percutaneous coronary intervention,’ write the authors. The study, they add, enrolled a highly selected patient population with mainly stable CAD and single de novo non complex target lesions. ‘As such, the study results should not be generalized to complex lesions, which are often encountered in clinical practice, such as bifurcations, heavily calcified lesions, diffuse disease, and thrombus.’

Notes to editor

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.
 
About ESC Congress 2015
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.